

Grifols provides additional information to CNMV

April 4, 2024

Today Grifols provided the additional information requested by Spain's National Securities Market Commission (CNMV) in its March 21, 2024, report, which concluded there were no significant errors in the company's financial statements.

Following the recommendations of the CNMV, Grifols provided a debt ratio according to the figures in the financial statements for 2022 and 2023 as per the P&L and balance sheet, respectively. The company, to be consistent with previous reporting periods, will continue to disclose its leverage ratio in accordance with its Credit Agreement.

The main difference between the debt ratio per the credit agreement and the debt ratio according to the financial statements (P&L and balance sheet) in 2023 are due to:

- The inclusion in EBITDA of adjustments for extraordinary, unusual or non-recurring expenses; adjustments for cost savings and operational improvements for the next 12 months.
- The exclusion of finance leasing related to plasma donation centers as part of debt in accordance with the credit agreement.

Additionally, the company detailed its EBITDA ratios and net financial debt as well as provided these figures specifically for the companies in which it has a non-controlling interest.

Grifols is dedicated to adopting all measures outlined in its CNMV filing, including any additional measure needed for quality and consistency of the information delivered to financial markets and investors. The company also pledges full adherence to European Securities and Markets Authority (ESMA) and CNMV guidelines and recommendations.

For more information, please see [related regulatory filing](#).